Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use-Reference-Cited by-同舟云学术

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Published:2023-03-10 Issue:4 Volume:14 Page:396-404
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Ito Satoru¹^ORCID,Otsuki Sachie¹,Ohsawa Hirokazu¹,Hirano Atsushi¹,Kazuno Hideki²,Yamashita Satoshi¹,Egami Kosuke³,Shibata Yoshihiro⁴,Yamamiya Ikuo¹,Yamashita Fumiaki¹,Kodama Yasuo¹,Funabashi Kaoru¹,Kazuno Hiromi¹,Komori Toshiharu⁵,Suzuki Satoshi¹,Sootome Hiroshi¹,Hirai Hiroshi¹,Sagara Takeshi¹

Affiliation:

1. Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan

2. Formulation Research Lab, CMC Division, Taiho Pharmaceutical Co. Ltd., Tokushima, Tokushima 771-0194, Japan

3. Intellectual Property Department, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan

4. MA Project Management Office, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan

5. Regulatory Affairs Department, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan

Funder

Taiho Pharmaceutical

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.3c00006

Reference22 articles.

1. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

2. AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

3. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

4. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

5. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect;European Journal of Medicinal Chemistry;2024-11

2. Futibatinib (Lytgobi): A Selective Irreversible FGFR1–4 Inhibitor;Chemistry and Pharmacology of Drug Discovery;2024-08-16

3. Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization;Bioorganic Chemistry;2024-07

4. The role of the methoxy group in approved drugs;European Journal of Medicinal Chemistry;2024-07

5. Property-Based Drug Design Merits a Nobel Prize;Journal of Medicinal Chemistry;2024-06-28